Business Wire12.11.17
The Medical Device Innovation Consortium (MDIC) President and CEO William V. Murray is stepping down effective Feb. 2, 2018, to return to the private sector.
“Over the past four years, it has been my honor and privilege to lead MDIC as we have grown from concept to an established part of the ecosystem in accelerating patient access to safe and effective life-changing innovation," Murray said. "I am extremely proud of what we have accomplished. The organization is fortunate to be led by a board of senior leaders throughout the medtech ecosystem, supported by a group of member volunteers and dedicated MDIC staff that give me great confidence we will achieve a smooth transition.”
“The Board of Directors for MDIC would like to thank Bill for his leadership and contribution to advancing regulatory science for patients and expanding into real world data coordination,” said MDIC Board Chairman Mike Minogue, president, CEO and chairman of Abiomed. “We wish him well going forward as he returns to the private sector to pursue other opportunities.”
“MDIC has made great progress under Bill’s leadership these past four years,” said Jeffrey Shuren, M.D., J.D., director of the U.S. Food and Drug Administration’s Center for Devices and Radiological Health. “The organization has evolved into an integral partner with patients, industry and the FDA in addressing the most challenging regulatory science issues required for faster, safer and more efficient development, assessment and review of life-changing medical technologies. The FDA looks forward to continued collaborations with MDIC and its new leadership.”
Murray added, “My decision to return to the private sector has been difficult and emotional; we have built something very unique and rewarding at MDIC. Announcing my intention three months prior to leaving was the right decision to allow MDIC to move forward in a planned manner. I want to thank the MDIC Board for their support as I worked through this process.”
The MDIC Board has initiated a search for the next CEO. Stated Minogue, “MDIC is an integral part of the medtech ecosystem, the board is committed to find the next CEO leader that has the vision, passion and commitment to build on MDIC’s success.”
Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market.
“Over the past four years, it has been my honor and privilege to lead MDIC as we have grown from concept to an established part of the ecosystem in accelerating patient access to safe and effective life-changing innovation," Murray said. "I am extremely proud of what we have accomplished. The organization is fortunate to be led by a board of senior leaders throughout the medtech ecosystem, supported by a group of member volunteers and dedicated MDIC staff that give me great confidence we will achieve a smooth transition.”
“The Board of Directors for MDIC would like to thank Bill for his leadership and contribution to advancing regulatory science for patients and expanding into real world data coordination,” said MDIC Board Chairman Mike Minogue, president, CEO and chairman of Abiomed. “We wish him well going forward as he returns to the private sector to pursue other opportunities.”
“MDIC has made great progress under Bill’s leadership these past four years,” said Jeffrey Shuren, M.D., J.D., director of the U.S. Food and Drug Administration’s Center for Devices and Radiological Health. “The organization has evolved into an integral partner with patients, industry and the FDA in addressing the most challenging regulatory science issues required for faster, safer and more efficient development, assessment and review of life-changing medical technologies. The FDA looks forward to continued collaborations with MDIC and its new leadership.”
Murray added, “My decision to return to the private sector has been difficult and emotional; we have built something very unique and rewarding at MDIC. Announcing my intention three months prior to leaving was the right decision to allow MDIC to move forward in a planned manner. I want to thank the MDIC Board for their support as I worked through this process.”
The MDIC Board has initiated a search for the next CEO. Stated Minogue, “MDIC is an integral part of the medtech ecosystem, the board is committed to find the next CEO leader that has the vision, passion and commitment to build on MDIC’s success.”
Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market.